Webdisclosure.com

Search

NEOVACS (EPA:ALNEV) NEOVACS AND KEPLER CHEUVREUX SIGN A FINANCING PROJECT

Directive transparence : information réglementée

23/10/2014 08:30
DGAP-News: Neovacs S.A. / Key word(s): Financing NEOVACS AND KEPLER CHEUVREUX SIGN A FINANCING PROJECT 23.10.2014 / 08:30 --------------------------------------------------------------------- NEOVACS AND KEPLER CHEUVREUX SIGN A FINANCING PROJECT Paris, 23 October 2014 - NEOVACS (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced the signing of a financing project with Kepler Cheuvreux. Neovacs has an innovative portfolio of vaccines in clinical and pre-clinical stage, which will need several years to develop until registration. Some of these products should be subject of a licensing or co-development agreement, assuring, thus a long lasting scientific partnership as well as the co-financing of common projects. In addition and in order to accompany its plan of development, Neovacs has already been able to agree with Kepler Cheuvreux on a financing tool, covering several years, including optional items, in order to be able to raise funds according to the evolution of the company's financial needs. Agreed in its principles by the management team of both companies, the implementation of this project will be subject of detailed information at a later stage. About Neovacs Neovacs is a biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by six patent families that run until at least 2023) Neovacs is focusing its development efforts on two active immunotherapies: TNF-Kinoid is being developed for the treatment of TNF-mediated autoimmune diseases such as rheumatoid arthritis and Crohn's disease, whereas IFN?-Kinoid is being developed for the indication of lupus. Neovacs is also conducting preclinical works on IFN?-Kinoid in certain chronic viral infections, VEGF-Kinoid in Age-related Macular Degeneration (AMD) and solid tumors, and IL-4-Kinoid for the treatment of allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. For more information on Neovacs, visit www.neovacs.fr Press & Financial Communication France - Publicis Stéphanie Tabouis Aubane de Gélis +33 (0) 1 44 82 46 35 +33 (0) 1 44 82 46 38 stéphanie.tabouis@consultants.publicis.fr aubane.de-gelis@consultants.publicis.fr --------------------------------------------------------------------- 23.10.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Neovacs S.A. 3-5, Impasse Reille 75014 Paris France Phone: +33 (0)1 53 10 93 00 Fax: +33 (0)1 53 10 93 03 E-mail: www.neovacs.fr Internet: info@neovacs.fr ISIN: FR0004032746 WKN: A1CVKR Listed: Freiverkehr in Stuttgart; Frankfurt in Open Market End of News DGAP News-Service --------------------------------------------------------------------- 292886 23.10.2014